Carregant...
Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need f...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Landes Bioscience
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4130285/ https://ncbi.nlm.nih.gov/pubmed/24316863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27426 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|